Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $19.94 million versus the consensus estimate of $17.81 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.